About
Mr. Schor is President and Chief Executive Officer of Adicet Bio. Mr. Schor led biotech…
Activity
-
🔔 We're ringing in a momentous occasion! 🔔 Today, Rapptors had the honor of ringing the closing bell at @Nasdaq to mark our recent IPO! This…
🔔 We're ringing in a momentous occasion! 🔔 Today, Rapptors had the honor of ringing the closing bell at @Nasdaq to mark our recent IPO! This…
Liked by Chen Schor
-
https://lnkd.in/dV7GTPcG
https://lnkd.in/dV7GTPcG
Shared by Chen Schor
-
Adicet is pleased to welcome to the team our new Vice President of Clinical Development, Dr. Benjamin Hsu! As Adicet builds out our pipeline…
Adicet is pleased to welcome to the team our new Vice President of Clinical Development, Dr. Benjamin Hsu! As Adicet builds out our pipeline…
Liked by Chen Schor
Experience
More activity by Chen
-
Outcome Capital is proud to have been selected by The Lifesciences Magazine as Top Life Sciences Advisory & Investment Banking Firm - 2024…
Outcome Capital is proud to have been selected by The Lifesciences Magazine as Top Life Sciences Advisory & Investment Banking Firm - 2024…
Liked by Chen Schor
-
Thanking our investors for the vote of confidence in the team, pipeline and our gamma-delta1 CAR T platform. We look forward to making a potentially…
Thanking our investors for the vote of confidence in the team, pipeline and our gamma-delta1 CAR T platform. We look forward to making a potentially…
Shared by Chen Schor
-
We are seeking a talented physician scientist (M.D., Ph.D) to join us on our mission to deliver potentially curative CAR T therapies for patients…
We are seeking a talented physician scientist (M.D., Ph.D) to join us on our mission to deliver potentially curative CAR T therapies for patients…
Shared by Chen Schor
-
At #ash23 , all of us at Johnson & Johnson Innovative Medicine are thrilled to be sharing new data across our multi-target, multi-platform…
At #ash23 , all of us at Johnson & Johnson Innovative Medicine are thrilled to be sharing new data across our multi-target, multi-platform…
Liked by Chen Schor
-
Last Monday, I had the honor of being named a "Woman to Watch" by Jewish Women International (JWI). It was an incredibly inspiring weekend of…
Last Monday, I had the honor of being named a "Woman to Watch" by Jewish Women International (JWI). It was an incredibly inspiring weekend of…
Liked by Chen Schor
-
It was a sincere pleasure working with Tim Surgenor and his team at Red Sky Partners, LLC. Best wishes to Phil Gotwals in this new role. cc:…
It was a sincere pleasure working with Tim Surgenor and his team at Red Sky Partners, LLC. Best wishes to Phil Gotwals in this new role. cc:…
Liked by Chen Schor
-
Dear Friends, So many of you asked how we are doing. Honestly, there are no words in English to completely describe it. How do you feel when you…
Dear Friends, So many of you asked how we are doing. Honestly, there are no words in English to completely describe it. How do you feel when you…
Liked by Chen Schor
-
Join us in welcoming Campbell Murray as a new member of Carbon’s Board of Directors! Currently a Partner at Agent Capital, Dr. Murray is an…
Join us in welcoming Campbell Murray as a new member of Carbon’s Board of Directors! Currently a Partner at Agent Capital, Dr. Murray is an…
Liked by Chen Schor
-
Our CEO Joel Schneider and founder Robert Kotin spoke with Rahul Chaturvedi Biotech2050 about the research that led to the founding of Carbon…
Our CEO Joel Schneider and founder Robert Kotin spoke with Rahul Chaturvedi Biotech2050 about the research that led to the founding of Carbon…
Liked by Chen Schor
-
On today’s #biotechhangout #JPM23 edition, Michael Yee, Daphne Zohar, Josh Schimmer and Tim Opler discuss what we learned from 2022 and looking…
On today’s #biotechhangout #JPM23 edition, Michael Yee, Daphne Zohar, Josh Schimmer and Tim Opler discuss what we learned from 2022 and looking…
Liked by Chen Schor
-
Adicet Bio Reports Positive Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma…
Adicet Bio Reports Positive Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma…
Posted by Chen Schor
-
https://lnkd.in/eP6pDX4N
https://lnkd.in/eP6pDX4N
Shared by Chen Schor
Explore collaborative articles
We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.
Explore More